Jiangsu Lianhuan Pharmaceutical Co., Ltd. (600513.SS) engages in the research, development, production, and sale of pharmaceuticals in China, with operations encompassing pharmaceutical manufacturing and distribution; it manufactures chemical raw materials, injections, solid preparations, and other dosage forms across multiple therapeutic categories including urinary system drugs such as epristeride tablets and tadalafil tablets; antihistamines including ebastine tablets, bepotastine besilate tablets, and terfenadine tablets; cardiovascular drugs such as felodipine tablets, clopidogrel bisulfate tablets, and milrinone injection; steroidal hormones including danazol capsules and suppositories; antibiotics such as azithromycin tablets, doxycycline hydrochloride tablets, and moxifloxacin hydrochloride tablets; and additional products like dapoxetine hydrochloride tablets for premature ejaculation, abiraterone acetate tablets for cancer treatment, sertraline hydrochloride capsules, temozolomide capsules, and metformin glipizide tablets. The company also wholesales chemical raw materials and pharmaceuticals, sells medical equipment and electronic products, and provides medical technology research, development, and transfer services; its products export to Southeast Asia, North America, South America, Europe, New Zealand, Australia, and other regions. Founded in 1999 by the Yangzhou Pharmaceutical Factory established in 1958 and listed on the Shanghai Stock Exchange in 2003, Jiangsu Lianhuan Pharmaceutical is headquartered in Yangzhou, Jiangsu Province, China, and holds national high-tech enterprise status with multiple provincial honors. Recent developments include selection in 2023 as one of the first world-class professional leading demonstration enterprises in Jiangsu and the only local state-owned enterprise in its city to receive this recognition; in 2025, its wholly-owned subsidiary acquired a 54% stake in Xinxiang Changle Pharmaceutical for nearly 202 million yuan to expand capabilities; strategic cooperation agreements signed in September 2025 by subsidiaries including Yangzhou Lianhuan Investment and Nanjing Lianzhi Pharmaceutical Technology with Chengdu Yazhong Biopharmaceutical to advance cardiovascular R&D and market transformation; regulatory approval in September 2025 for famotidine injection; a planned 15 million yuan investment announced in November 2024 for joint antithrombotic drug R&D with Nanjing University; multiple capital increases in 2025 totaling over 140 million yuan to subsidiaries like Yangzhou Lianhuan Investment and Lianhuan (Anqing) to support strategic expansion despite ongoing losses in those units; and successive approvals for generic drugs targeting respiratory systems amid rising R&D expenses.